The Watchlist: The Story Behind the Stock

In Episode 1 of The Watchlist, we sit down with ImmuPharma CEO Tim McCarthy for a deep dive into their groundbreaking autoimmune treatment, P140, and the company's investment potential. This is a must-listen for retail investors interested in the biotech and pharmaceutical sectors.

In this interview, we cover:

• The Science: How the P140 "immunormalizer" technology could put patients into remission by restoring immune balance without the common side effects.

• The Market: The massive opportunity within the $100 billion autoimmune disease market, which affects 400 million patients worldwide.

• Valuation & Deals: CEO Tim McCarthy addresses the recent share price rise, company valuation, and the timeline for securing major pharma partnering deals.

• Financial Health: A clear breakdown of ImmuPharma's cash runway and funding strategy for future clinical trials.

Learn more about the company at imufarmmer.co.uk.

This interview was originally recorded for video, which you can view here: https://youtu.be/f4U-96wP_fA

Chapters0:00 - Introduction: The P140 "Immunormalizer" Breakthrough 0:52 - How P140 Aims to Revolutionize Autoimmune Treatment 2:38 - Valuation, Timelines & Confidence in Landing a Pharma Deal 4:30 - The Funding Strategy: A Solid Cash Runway & Non-Dilutive Deals 5:50 - Closing Remarks

Disclaimer: This content is created in partnership with ImmuPharma and is for informational purposes only and should not be considered financial or investment advice. The views expressed are those of the participants. Please conduct your own research before making any investment decisions. For our full disclaimer, visit: https://themarketonline.ca/disclaimer